Is GRI or GSK more undervalued in 2026?

CirclFi compares GRI Bio, Inc. (GRI) and GSK plc (GSK) using 13 institutional-grade valuation models. GRI has a Quality of Company score of 3.9/10 while GSK scores 8.7/10.

Which is a better buy — GRI or GSK?

Compare intrinsic values from 13 independent models against current market prices. CirclFi also calculates Value Trap scores. This is not financial advice — conduct your own analysis.

How do GRI and GSK valuations compare?

GRI at $2.06 and GSK at $50.54 are compared across Bayesian DCF, EPV, EROIC Spread, First Chicago, Markov DDM, and 8 additional models.

GRI vs GSK Valuation Comparison 2026 — Intrinsic Value Analysis

GRI

Pharmaceutical Preparations

GRI Bio, Inc.

Quality

3.9

out of 10

Value Trap

SAFE

Price

$2.06

Last close

Models

6/13

Active

GSK

Pharmaceutical Preparations

GSK plc

Quality

8.7

out of 10

Value Trap

SAFE

Price

$50.54

Last close

Models

12/13

Active

Model-by-Model Comparison

Model	Type	GRI Fair Value	GRI Upside	GSK Fair Value	GSK Upside
Bayesian DCF	Intrinsic	$3.99	+93.7%	$43.74	-13.5%
Earnings Power Value	Intrinsic	—	—	$56.37	+11.5%
EROIC Spread	Intrinsic	$•••.••	••.•%	$•••.••	••.•%
First Chicago	Scenario	$•••.••	••.•%	$•••.••	••.•%
Markov DDM	Intrinsic	$•••.••	••.•%	$•••.••	••.•%
ML-RIV	Intrinsic	$0.05	-97.9%	$85.31	+68.8%
PWERM	Option-Based	$•••.••	••.•%	$•••.••	••.•%
Regime Cross-Sectional	Relative	$•••.••	••.•%	$•••.••	••.•%
Sentiment SOTP	Hybrid	$•••.••	••.•%	$•••.••	••.•%
CUCE Ensemble	Ensemble	$•••.••	••.•%	$•••.••	••.•%
FTNN Topology	Relative	$•••.••	••.•%	$•••.••	••.•%
RCMH-DCF	Intrinsic	$•••.••	••.•%	$•••.••	••.•%

🔒

Unlock Full 13-Model Comparison

Access all valuation models for GRI vs GSK — including EROIC Spread, First Chicago, Markov DDM, PWERM, and 7 more.

Access Full Analysis — From $27/mo →

GRI vs GSK — Which Stock Is More Undervalued?

GSK scores higher with a 8.7/10 quality rating vs GRI's 3.9/10. Both stocks are analyzed daily using SEC EDGAR filings across 13 independent models.

Comparing GRI Bio, Inc. (GRI) and GSK plc (GSK) across 13 institutional-grade valuation models reveals how each company's intrinsic value stacks up against its market price. CirclFi's engine processes SEC EDGAR 10-K and 10-Q filings, FRED macroeconomic data, and GDELT news sentiment to generate independent fair value estimates daily.

GRI currently trades at $2.06 with a QOC of 3.9/10, while GSK trades at $50.54 with a QOC of 8.7/10.

Both companies are analyzed with models spanning intrinsic (Bayesian DCF, EPV), scenario-based (First Chicago), regime-switching (Markov DDM, RCMH-DCF), machine learning (ML-RIV, FTNN Topology), and ensemble methods (CUCE).